NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News $48.65 +0.65 (+1.35%) (As of 01:44 PM ET) Add Compare Share Share Today's Range$47.44▼$48.6650-Day Range$37.29▼$48.0052-Week Range$22.31▼$52.23Volume39,294 shsAverage Volume90,219 shsMarket Capitalization$874.24 millionP/E RatioN/ADividend YieldN/APrice Target$55.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ANI Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15.0% Upside$55.67 Price TargetShort InterestHealthy1.87% of Shares Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment1.03Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth37.11%From $2.56 to $3.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.69 out of 5 starsMedical Sector66th out of 980 stocksPharmaceutical Preparations Industry26th out of 485 stocks 2.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.67, ANI Pharmaceuticals has a forecasted upside of 15.0% from its current price of $48.41.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.87% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 15.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 39.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antiplatelet medication", "Antifungal medication (D01) ", and "Cyclophosphamide" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.49. Previous Next 3.9 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ANI Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for ANIP on MarketBeat in the last 30 days. MarketBeat Follows3 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders28.50% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.89% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 37.11% in the coming year, from $2.56 to $3.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -28.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -28.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ANI Pharmaceuticals (NASDAQ:ANIP) StockANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.Read More Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Stock News HeadlinesJune 3, 2023 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Rating Increased to Buy at StockNews.comMay 31, 2023 | msn.comANI Pharmaceuticals: Strong Revenue Growth And ANDA ApprovalsJune 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.May 22, 2023 | finance.yahoo.comANI Pharmaceuticals to Present at the Jefferies Healthcare ConferenceMay 22, 2023 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Rating Lowered to Hold at StockNews.comMay 16, 2023 | finance.yahoo.comANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 14, 2023 | americanbankingnews.comCantor Fitzgerald Weighs in on ANI Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:ANIP)May 12, 2023 | bizjournals.comANI Pharmaceuticals plans to raise $75 million in stock offeringJune 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.May 12, 2023 | markets.businessinsider.comANI Pharmaceuticals Drops 10% After Pricing Share OfferingMay 12, 2023 | finance.yahoo.comANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common StockMay 11, 2023 | seekingalpha.comANI Pharmaceuticals announces proposed stock offering, shares fall 6% after hoursMay 11, 2023 | finance.yahoo.comANI Pharmaceuticals Announces Proposed Public Offering of Common StockMay 11, 2023 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $59.00May 11, 2023 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Up After Analyst UpgradeMay 10, 2023 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2023 Earnings GuidanceMay 9, 2023 | msn.comHC Wainwright & Co. Maintains ANI Pharmaceuticals (ANIP) Buy RecommendationMay 9, 2023 | finance.yahoo.comQ1 2023 ANI Pharmaceuticals Inc Earnings CallMay 9, 2023 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Price Target Increased to $60.00 by Analysts at HC WainwrightMay 8, 2023 | marketwatch.comAni Pharmaceuticals Stock Up 17% After Boost to Guidance, 1Q Earnings BeatMay 8, 2023 | markets.businessinsider.comANI Pharmaceuticals Jumps On Upbeat Results, Increased Outlook Above ViewMay 8, 2023 | msn.comANI Pharmaceuticals soars ~10% after Q1 beat, raises outlook amid rare disease focusMay 8, 2023 | finance.yahoo.comWhy ANI Pharmaceuticals Stock Is Soaring TodayMay 8, 2023 | finance.yahoo.comANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 GuidanceMay 8, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue EstimatesMay 7, 2023 | americanbankingnews.comANI Pharmaceuticals (ANIP) Set to Announce Quarterly Earnings on MondayMay 5, 2023 | msn.comEarnings Preview For ANI PharmaceuticalsSee More Headlines ANIP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Company Calendar Last Earnings3/09/2023Today6/05/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees601Year FoundedN/APrice Target and Rating Average Stock Price Forecast$55.67 High Stock Price Forecast$60.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+16.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E Ratio18.75 P/E GrowthN/ANet Income$-47,900,000.00 Net Margins-7.34% Pretax Margin-9.65% Return on Equity10.60% Return on Assets4.40% Debt Debt-to-Equity Ratio0.91 Current Ratio2.90 Quick Ratio2.08 Sales & Book Value Annual Sales$316.39 million Price / Sales2.73 Cash Flow$4.04 per share Price / Cash Flow11.89 Book Value$17.50 per share Price / Book2.74Miscellaneous Outstanding Shares17,970,000Free Float12,851,000Market Cap$862.56 million OptionableOptionable Beta1.02 Key ExecutivesNikhil LalwaniPresident, Chief Executive Officer & DirectorJames G. MarkenSenior VP-Operations & Product DevelopmentStephen P. CareyChief Financial Officer & Senior VP-FinanceMuthusamy ShanmugamDirector & Head-Research & DevelopmentMary PaoChief Medical OfficerKey CompetitorsCogent BiosciencesNASDAQ:COGTMersana TherapeuticsNASDAQ:MRSNEQRxNASDAQ:EQRXPharming GroupNASDAQ:PHARPureTech HealthNASDAQ:PRTCView All CompetitorsInsiders & InstitutionsBrandywine Global Investment Management LLCBought 2,185 shares on 5/25/2023Ownership: 0.723%JPMorgan Chase & Co.Bought 4,427 shares on 5/18/2023Ownership: 0.242%New York State Common Retirement FundBought 6,381 shares on 5/18/2023Ownership: 0.088%Thrivent Financial for LutheransSold 424 shares on 5/17/2023Ownership: 0.067%Susquehanna International Group LLPSold 1,700 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ANIP Stock - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price forecast for 2023? 3 analysts have issued twelve-month target prices for ANI Pharmaceuticals' stock. Their ANIP share price forecasts range from $48.00 to $60.00. On average, they anticipate the company's share price to reach $55.67 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2023? ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of the year. Since then, ANIP stock has increased by 19.3% and is now trading at $48.00. View the best growth stocks for 2023 here. Are investors shorting ANI Pharmaceuticals? ANI Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 336,900 shares, a decline of 15.9% from the April 30th total of 400,700 shares. Based on an average daily volume of 104,000 shares, the days-to-cover ratio is presently 3.2 days. View ANI Pharmaceuticals' Short Interest. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our ANIP earnings forecast. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Thursday, March, 9th. The specialty pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.10. The specialty pharmaceutical company had revenue of $94.23 million for the quarter, compared to analysts' expectations of $86.76 million. ANI Pharmaceuticals had a negative net margin of 7.34% and a positive trailing twelve-month return on equity of 10.60%. What ETFs hold ANI Pharmaceuticals' stock? ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Syntax Stratified SmallCap ETF (SSLY), Principal Healthcare Innovators ETF (BTEC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of $2.99-$3.45 for the period, compared to the consensus EPS estimate of $2.43. The company issued revenue guidance of $385.00 million-$410.00 million, compared to the consensus revenue estimate of $361.82 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). What is ANI Pharmaceuticals' stock symbol? ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP." Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.10%), Rubric Capital Management LP (3.61%), Dimensional Fund Advisors LP (3.04%), William Blair Investment Management LLC (3.02%), Global Alpha Capital Management Ltd. (2.65%) and State Street Corp (2.56%). Insiders that own company stock include James G Marken, Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ANI Pharmaceuticals' stock price today? One share of ANIP stock can currently be purchased for approximately $48.00. How much money does ANI Pharmaceuticals make? ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $862.56 million and generates $316.39 million in revenue each year. The specialty pharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. How many employees does ANI Pharmaceuticals have? The company employs 601 workers across the globe. How can I contact ANI Pharmaceuticals? ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540. This page (NASDAQ:ANIP) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.